Drug intelligence / Profile preview

Formula Pinggan

Development stage: Unknown
Lead developer: Hepatitis B Foundation
Administration: Oral

Overview

Formula Pinggan is a Traditional Chinese Medicine (TCM) formula currently under investigation for the treatment of liver cirrhosis. It is administered orally as a tablet. A pilot study evaluated its efficacy and safety at a dosage of 1.6g (two 0.8 gm tablets) three times daily for 24 weeks. The specific active ingredients and their detailed mechanisms of action are not publicly detailed for this particular formulation and indication.

Beyond the preview

Go deeper on Formula Pinggan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Formula Pinggan.

Explore the full profile